title: Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid.
abstract: Omega-3 fatty acids have received increasing interest due to their effects in stabilizing plasmatic membranes and regulating cell signaling. The efficacy of omega-3 fatty acids in psychiatric disorders, in particular mood disorders, has been studied. There have been two trials on eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) in the treatment of borderline personality disorder (BPD). The present 12-week controlled trial aimed to assess the efficacy of the association of EPA and DHA with valproic acid, compared to single valproic acid, in 43 consecutive BPD outpatients. Participants were evaluated at baseline and after 12 weeks with: Clinical Global Impression - Severity (CGI-S), Hamilton Scales for depression and anxiety (HAM-D, HAM-A), Social and Occupational Functioning Assessment Scale (SOFAS), borderline personality disorder severity index (BPDSI), Barratt Impulsiveness Scale - version 11 (BIS-11), Modified Overt Aggression Scale (MOAS), Self-Harm Inventory (SHI) and Dosage Record Treatment Emergent Symptom Scale (DOTES).
authors.affiliation: Department of Neuroscience, University of Turin, Turin, Italy.
authors.forename: Silvio
authors.initials: S
authors.lastname: Bellino
authors.forename: Paola
authors.initials: P
authors.lastname: Bozzatello
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Rocca
authors.forename: Filippo
authors.initials: F
authors.lastname: Bogetto
mesh_terms: D000328:Adult; D018692:Antimanic Agents / Q000008:administration & dosage*; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D014635:Valproic Acid / Q000008:administration & dosage*
chemical_list: D018692:Antimanic Agents; D015525:Fatty Acids, Omega-3; D014635:Valproic Acid
keywords: Borderline personality disorder; docosahexanoic acid; efficacy; eicosapentanoic acid; mood stabilizer; omega-3 fatty acid; psychiatric disorders; tolerability; valproic acid